Epstein-Barr Virus-related Posttransplant Lymphoproliferative Disorder in Children: A Single-institution Experience

Area of Science:

• Pediatric Hematology/Oncology
• Transplant Immunology
• Oncology

Background:

• Posttransplant lymphoproliferative disorder (PTLD) is a rare but serious complication following allogeneic hematopoietic stem cell transplantation (HSCT).
• EBV-driven PTLD is characterized by diffuse proliferation of lymphoid cells and often expresses Epstein-Barr virus latent membrane protein-1 (LMP-1).
• Pediatric PTLD post-HSCT presents unique challenges in diagnosis and management.

Purpose of the Study:

• To report on pediatric cases of PTLD following allogeneic HSCT.
• To evaluate the efficacy of rituximab combined with immunosuppression reduction in treating pediatric PTLD.
• To explore potential associations between underlying conditions and PTLD development.

Main Methods:

• Biopsy-proven PTLD cases in pediatric patients undergoing allogeneic HSCT were identified.
• Immunohistochemistry was performed to assess for latent membrane protein-1 (LMP-1) expression.
• Patients received rituximab treatment and had their immunosuppression reduced.

Main Results:

• Four pediatric cases of PTLD post-HSCT were identified, all showing diffuse LMP-1 staining.
• The median age at transplant was 10.1 years, with PTLD diagnosis occurring a median of 5.5 months post-HSCT.
• All patients treated with rituximab and reduced immunosuppression survived, with a median follow-up of 27 months.

Conclusions:

• Combined reduction of immunosuppression and rituximab therapy demonstrates significant response rates in pediatric PTLD post-HSCT.
• Severe aplastic anemia may be closely associated with PTLD development in children.
• This approach offers a promising strategy for managing this infrequent but potentially lethal complication.